论文部分内容阅读
轻症溃疡性结肠炎的治疗,目前首选柳氮磺胺吡啶(SASP)3～4g/d口服。SASP是磺胺吡啶(sulphapyridine,SP)与5-对氨水杨酸(5-am-inosalicylicacid,5-ASA)的偶氮化合物,口服后大部分在结肠内经细菌作用切断偶氮结合,分解为SP和5-ASA。SP很容易吸收,5-ASA约1/3在肠内吸收,2/3从大便排泄。对SASP的有效成分的研究结果表明,SASP的有效成分是5-ASA,SP则无效。5-ASA的作用机理还不十分清楚,有作者报告与抑制前列腺素(PG)和清除活性氧而抑制肠上皮细胞的DNA损失有关。
The treatment of mild ulcerative colitis, the preferred choice of sulfasalazine (SASP) 3 ~ 4g / d orally. SASP is an azo compound of sulphapyridine (SP) and 5-amosalicylic acid (5-ASA). After oral administration, most of the azo compounds are cleaved azo by bacterial action in the colon and decomposed into SP and 5-ASA. SP is easily absorbed, about 1/3 of the 5-ASA is absorbed in the intestine, and 2/3 is excreted in the stool. The study on the active ingredients of SASP showed that the active ingredient of SASP is 5-ASA, while the SP is ineffective. The mechanism of action of 5-ASA is not well understood. Some authors report that inhibition of prostaglandin (PG) and scavenging reactive oxygen species to inhibit intestinal epithelial DNA loss.